drugset

drugset / Trial / NCT00214994

Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.

NCT00214994 ↗

Phase 3 Completed Cephalon

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.

Timeline

Start: 2005-01
Primary completion: —
Completion: 2006-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tiagabine	Small molecule	16 mg	—

Indications